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Abstract
Background: Breast cancer subtype can be classified using standard clinical markers (estrogen receptor (ER), progesterone
receptor (PR) and human epidermal growth factor receptor 2 (HER2)), supplemented with additional markers. However,
automated biomarker scoring and classification schemes have not been standardized. The aim of this study was to optimize
tumor classification using automated methods in order to describe subtype frequency in the African American Breast Cancer
Epidemiology and Risk (AMBER) consortium.
Methods: Using immunohistochemistry (IHC), we quantified the expression of ER, PR, HER2, the proliferation marker Ki67,
and two basal-like biomarkers, epidermal growth factor receptor (EGFR) and cytokeratin (CK)5/6, in 1381 invasive breast
tumors from African American women. RNA-based (prediction analysis of microarray 50 (PAM50)) subtype, available for
574 (42%) cases, was used to optimize classification. Subtype frequency was calculated, and associations between subtype
and tumor characteristics were estimated using logistic regression.
Results: Relative to ER, PR and HER2 from medical records, central IHC staining and the addition of Ki67 or combined
tumor grade improved accuracy for classifying PAM50-based luminal subtypes. Few triple negative cases (< 2%) lacked
EGFR and CK5/6 expression, thereby providing little improvement in accuracy for identifying basal-like tumors. Relative
to luminal A subtype, all other subtypes had higher combined grade and were larger, and ER-/HER2+ tumors were more
often lymph node positive and late stage tumors. The frequency of basal-like tumors was 31%, exceeded only slightly by
luminal A tumors (37%).
Conclusions: Our findings indicate that automated IHC-based classification produces tumor subtype frequencies
approximating those from PAM50-based classification and highlight high frequency of basal-like and low frequency
of luminal A breast cancer in a large study of African American women.
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Background
Breast cancer comprises several tumor subtypes with dis-
tinct etiologies and clinical outcomes [1, 2]. However, high
assay cost and limited amounts of archived tumor tissue
may prevent utilization of RNA-based (e.g. prediction ana-
lysis of microarray 50 (PAM50)) subtype classification
methods in epidemiologic studies. Surrogate immunohis-
tochemistry (IHC)-based subtype classification schemes
are widely used, and even emphasized in St. Gallen guide-
lines [3]. Specifically, quantitative IHC for Ki67 and pro-
gesterone receptor (PR) is recommended for classification
of luminal (estrogen receptor (ER) positive) subtypes,
while cytokeratin (CK) 5/6 and epidermal growth factor
receptor (EGFR) are recommended to accurately identify
basal-like breast cancers among tumors that are negative
for all three standard clinical markers (ER, PR, and human
epidermal growth factor receptor 2 (HER2)). However,
thresholds for categorizing these IHC-based biomarkers
have been predominantly selected based on clinical
samples, and have not been optimized for epidemiologic
studies or for studies using automated digital pathology
approaches for tumor subtyping.
We quantified the expression of six tumor biomarkers
using automated methods for scoring IHC staining of
tissue microarrays (TMAs) comprising 1381 cases of
invasive breast cancer in African American (AA) women
from the African American Breast Cancer Epidemiology
and Risk (AMBER) consortium [4]. The aim of this study
was to optimize IHC-based tumor classification with
respect to PAM50-based subtype, and to describe the fre-
quency and characteristics of breast cancer subtypes in
the AMBER consortium.
Methods
Study population
This analysis is based on data from 1552 breast cancer
cases in the AMBER consortium [4] for which paraffin-
embedded tumor tissue was available on TMAs. Cases
were from the Carolina Breast Cancer Study phase 3
(CBCS, n = 819), the Black Women’s Health Study
(BWHS, n = 326) and the Women’s Circle of Health
Study (WCHS, n = 407). The CBCS was approved by
the Institutional Review Board at the University of North
Carolina at Chapel Hill School of Medicine. The BWHS
was approved by the Institutional Review Board at the
Boston University School of Medicine. The WCHS was
approved by the Institutional Review Boards at the
University of Medicine and Dentistry of New Jersey
(presently Rutgers University), Mount Sinai School of
Medicine, and Roswell Park Cancer Institute. Written
informed consent was obtained from each participant.
Combined grade, tumor size, lymph node status, and
tumor stage were abstracted from medical records, and
these tumor characteristics were available for 98%, 100%,
97%, and 98% of all study participants, respectively.
Combined grade was also centrally assigned by a breast
pathologist (JG for CBCS; HH and TK for WCHS and
BWHS) using the Nottingham breast cancer grading sys-
tem [5], and was available for 96% of cases.
Immunohistochemistry staining and quantification
Paraffin-embedded tumor blocks were requested from
clinical pathology facilities, and TMA construction and
sectioning was carried out for CBCS at the Translational
Pathology Lab (TPL), University of North Carolina at
Chapel Hill (UNC) and at Roswell Park Cancer Institute
(RPCI) for BWHS and WCHS [6]. All central IHC stain-
ing was performed at the UNC TPL; detailed methods
for ER, PR and HER2 have been described [6], and are
provided in Additional file 1: Supplementary Methods
for Ki67, EGFR and CK5/6. Automated quantification of
IHC staining was performed using a Genie classifier and
Nuclear v9 (for ER, PR, and Ki67) and Membrane v9
(for HER2, EGFR, and CK5/6) algorithms (Aperio
Technologies, Vista, CA, USA) [6]. For all six bio-
markers, the Genie classifier was used to eliminate re-
gions of folded tissue and other artifacts to reduce false
positives. For ER, PR and HER2, the Genie classifier was
used to exclude stromal cells, thereby enriching for
tumor epithelium. For CK5/6, the Genie classifier was
designed to reduce the number of positive myoepithelial
cells included in the analysis.
Immunohistochemistry-based biomarker thresholds
We used previously described core-to-case collapsing
methods to define biomarker status [6]. For ER, PR,
HER2, and Ki67, average biomarker expression across all
cores for a given case was weighted by the cellularity of
each core. For EGFR and CK5/6, we assigned positive sta-
tus to the case if any core was positive, given that these
biomarkers are more heterogeneously expressed than ER
and PR [7]. Indeed, manual review of 26 PAM50-defined
basal-like tumors revealed heterogeneous expression of
CK5/6 or EGFR in 10 (38%) cases, whereas our prior work
identified manually confirmed ER, PR, or HER2 hetero-
geneity in < 10% of cases [7].
A 10% threshold for ER and PR biomarker expression
was applied to maximize agreement with RNA-based
intrinsic subtype and with medical records, as previously
published in the AMBER consortium [6]. We explored a
20% threshold to classify PR status, as recommended by
St. Gallen guidelines [3] based on work by Prat et al. [8].
We identified an optimal Ki67 threshold by generating a re-
ceiver operating characteristic (ROC) curve among HER2-
negative luminal tumors and applying the Youden method
[9] to maximize the sum of the sensitivity and specificity
for PAM50-defined luminal B tumors (Additional file 2:
Figure S1). This method identified a threshold of 7.6%, and
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we rounded this threshold to the nearest integer (8%). We
repeated ROC curve analysis among all luminal cases
regardless of IHC-based HER2 status, identifying an opti-
mal Ki67 threshold of 7.1%. We applied ≥ 1% thresholds to
classify EGFR and CK5/6 status, given that previous studies
recommended that EGFR and CK5/6 expression be defined
as any positive staining [10, 11]. We validated this threshold
using manual review of a subset of 26 PAM50-defined
basal-like cases, finding that automated scoring correctly
classified basal-like biomarker expression in 25 of 26 (>
96%) manually reviewed PAM50-defined basal-like cases
(data not shown). In exploratory analysis, we generated
ROC curves among IHC-based triple negative cases to select
study-specific EGFR and CK5/6 thresholds for identifying
PAM50-defined basal-like tumors. We found a 2% CK5/6
threshold to be optimal for identifying basal-like breast can-
cer in the AMBER consortium, while EGFR expression did
not distinguish triple negative basal-like cases from triple
negative cases that were not basal-like (data not shown).
Of 1552 cases in total, 83 (5%) were missing one or
more biomarkers such that IHC-based subtype could not
be defined. A further 81 (5%) had equivocal (2+) HER2
status and were therefore unable to be classified, leaving a
total of 1381 cases with IHC-based subtype for analysis.
RNA-based subtyping
Nanostring assays were used to measure the PAM50 gene
signature in 488 cases from CBCS and 145 cases from
BWHS, and were performed in the Rapid Adoption
Molecular laboratory at UNC. For CBCS, two 1.0-mm
tumor cores from the tumor block used for TMA con-
struction were sampled within tumor regions circled by a
study pathologist (J. Geradts or L.B. Thorne) and pooled
for analysis. The areas surrounding the holes left by the
cores were subsequently examined by a study pathologist
to confirm high tumor cellularity in the cores used for
RNA extraction. For BWHS, 10-μm paraffin sections on
uncharged slides were scraped for analysis. The PAM50
predictor was performed as previously described [12] to
classify tumors into intrinsic subtypes (luminal A, luminal
B, HER2-enriched, basal-like, normal-like). Of 1381 cases
with IHC-based subtype, 574 (40%) also had RNA-based
PAM50 subtype (n = 449 CBCS cases and n = 125 BWHS
cases). Tumors classified as normal-like (n = 22) were
treated as missing PAM50 subtype, given that this classifi-
cation is thought to arise from extensive normal epithelial
or stromal content in the tumor [13]. Indeed, we found
that median tumor cellularity was significantly lower
among normal-like cases than other subtypes (2464 vs.
5543 cells per core; rank-sum test p < 0.001). Relative to
cases without PAM50 data, cases with PAM50 data were
younger at diagnosis, had larger tumors, higher combined
grade and higher tumor stage and were more likely to be
ER-negative and PR-negative; there were no differences in
lymph node or HER2 status.
Statistical analysis
Kernel density plots of Ki67 and PR expression in PAM50-
defined luminal A and luminal B subtypes were con-
structed, overall and restricted to tumors that were HER2-
negative by IHC. We compared sensitivity (true positive/
(true positive + false negative)), specificity (true negative/
(true negative + false positive)) and accuracy ((true positive
+ true negative)/total cases) of IHC-based classification
schemes for identifying luminal A and luminal B PAM50-
based subtypes.
We examined the frequency of IHC-based subtypes in
the AMBER consortium overall and across contributing
studies. Our findings were similar whether or not CBCS
subtype frequencies were weighted for sampling scheme,
and we chose to present weighted percentages. Multi-
nomial logistic regression was used to generate odds ratios
(ORs) and 95% confidence intervals (CIs) for associations
between age, menopause status, and IHC-based subtype,
treating luminal A cases as the referent group. We also
used multinomial logistic regression to examine differ-
ences in tumor characteristics across IHC-based subtypes.
In sensitivity analysis, we adjusted these models for study
site. Statistical analyses were conducted using STATA
version 13.1 (Stata Corp., College Station, TX, USA).
Results
Immunohistochemistry-based classification of non-basal-
like breast cancer
Subtype classification using three biomarkers (ER, PR, and
HER2) produced high sensitivity for luminal A (82%), but
low sensitivity for luminal B tumors (20%; Table 1). The
addition of combined tumor grade substantially increased
sensitivity for classification of luminal B tumors, resulting
in improved overall accuracy for both luminal A (81%
with grade vs. 73% without) and luminal B classification
(81% with grade vs. 79% without). Similar gains in accur-
acy were observed when adding combined grade to three
biomarker medical record-based classification, although
the accuracy of central IHC-based classification was
slightly better than medical record-based classification
overall (Additional file 3: Table S1).
St. Gallen guidelines recommend the use of quantitative
PR and Ki67 for classification of hormone receptor-positive,
HER2-negative tumors [3]. However, we found similar PR
expression levels in HER2-negative luminal A and B tumors
(Additional file 4: Figure S2) and, relative to a 10% threshold,
a 20% PR threshold (as recommended by St. Gallen guide-
lines [3]) had reduced accuracy for identifying luminal
tumors (data not shown). In contrast, the addition of Ki67
improved accuracy for identifying luminal tumors relative to
three biomarkers alone (80% vs. 73% for luminal A, and
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81% vs. 79% for luminal B tumors; Table 1), comparable to
the effect of adding combined grade.
Recent data show that not all luminal A tumors are
HER2-negative [14]. Indeed, 9–11% of PAM50-based
luminal A tumors in the AMBER consortium were
HER2-positive (based on HER2 status from central IHC
staining and medical records, respectively). As such, we
removed HER2 from the luminal classification scheme
and this produced very similar, if slightly improved,
accuracy for identifying PAM50-defined luminal sub-
types, relative to the three biomarker + Ki67 scheme
(Table 1). Finally, we explored the higher Ki67 thresh-
olds used in other studies [3, 15], but this reduced sensi-
tivity for luminal B cases and decreased overall accuracy
for distinguishing luminal subtypes in the AMBER
consortium, illustrating the importance of study-specific
Ki67 thresholds as recommended by St. Gallen guide-
lines (Additional file 5: Table S2).
Additional biomarkers for accurate IHC-based classifi-
cation of HER2-enriched tumors have not been identi-
fied. Therefore, we applied the standard definition of
ER-/HER2+, which yielded 45% sensitivity, 97% specifi-
city, and 90% accuracy (Fig. 1), in line with our previous
findings [6]. Given the low sensitivity for PAM50-based
HER2-enriched tumors using this classification scheme,
we refer to this subtype as ER-/HER2+.
Immunohistochemistry-based classification of basal-like
breast cancer
IHC-based classification using triple negative status alone
(ER-, PR-, and HER2-) produced high sensitivity for
PAM50-defined basal-like breast cancer (84%; Fig. 1 and
Table 2). The addition of EGFR and CK5/6 did not affect
accuracy, as extremely few triple negative cases (n = 7; <
2%) lacked expression of both basal-like biomarkers. Rela-
tive to triple negative status with ≥ 1% EGFR or CK5/6 ex-
pression, the use of a 2% CK5/6 threshold without EGFR
resulted in higher specificity (91% vs. 96%, respectively) but
lower sensitivity for basal-like tumors (83% vs. 53%, re-
spectively), and produced a relatively large proportion of
triple negative tumors that were not basal-like (41% of all
triple negative cases; Table 2). Given that the majority
(83%) of triple negative tumors in the AMBER consortium
was classified as basal-like using PAM50, we proceeded
with the 1% threshold for EGFR or CK5/6 expression in
order to maximize sensitivity and overall accuracy for
PAM50-based basal-like breast cancer, and to limit the
number of tumors misclassified as triple negative non-
basal-like.
Frequency and characteristics of six-biomarker
immunohistochemistry-based breast cancer subtypes
Using the optimized six biomarker IHC-based subtype
classification scheme, the frequency of basal-like breast
cancer in the AMBER consortium was 31%, while the fre-
quency of luminal A and luminal B cancers was 37% and
25%, respectively (Table 3). ER-/HER2+ cancers comprised
8% of all cases. Luminal A cancers were more frequent in
the BWHS than in the CBCS (46% vs. 32% luminal A)
while luminal B and basal-like cancers were more frequent
in the CBCS than in the BWHS (29% vs. 17% luminal B;
33% vs. 28% basal-like).
The frequency of luminal B tumors in the AMBER
consortium did not differ from that of luminal A tumors
with respect to age or menopausal status at diagnosis
(Table 4). However, ER-/HER2+ and basal-like cancers
were significantly more frequent at younger ages. Results
were similar when ORs were adjusted for AMBER study
site (Additional file 6: Table S3).
Relative to luminal A breast cancer, all other subtypes
had higher combined grade and were larger (Table 5).
However, only ER-/HER2+ tumors were later stage and
more likely to be lymph node positive, relative to luminal
A tumors.
Discussion
Accurate classification of tumor subtype is critical for
understanding clinical and etiologic heterogeneity in breast
cancer. Using automated methods to score central bio-
marker data from 1381 cases among African Americans
(AAs) in the AMBER consortium, we optimized IHC-based
Table 1 Classification of luminal breast cancer cases using data
from central immunohistochemistry assays in the AMBER
consortium
Subtype
frequency,
n (%)
Sensitivity
for PAM50
subtype
Specificity
for PAM50
subtype
Accuracy
for PAM50
subtype
HR/HER2
Luminal A HR+/HER2- 606 (50) 82% 69% 73%
Luminal B HR+/HER2+ 140 (11) 20% 94% 79%
HR/HER2/
combined
grade
Luminal A HR+/HER2-,
low/intermediate
grade
448 (37) 69% 86% 81%
Luminal B HR+/HER2+,
or HR+/HER2-,
high grade
298 (24) 64% 85% 81%
HR/HER2/Ki67
Luminal A HR+/HER2-,
low Ki67a
420 (34) 66% 87% 80%
Luminal B HR+/HER2+,
or HR+/HER2-,
high Ki67a
326 (27) 68% 84% 81%
HR/Ki67
Luminal A HR+, low Ki67b 453 (37) 67% 86% 80%
Luminal B HR+, high Ki67b 293 (24) 68% 85% 82%
HR hormone receptor, PAM50 prediction analysis of microarray 50, HER2 human
epidermal growth factor receptor 2
aKi67 threshold of 8%, as identified by ROC analysis among HER2-negative
luminal tumors
bKi67 threshold of 7%, as identified by ROC analysis among all luminal tumors
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tumor classification to maximize sensitivity, specificity, and
accuracy with respect to PAM50 subtype. Implementing
our optimized IHC-based classification scheme, we report a
high frequency of basal-like breast cancer in the AMBER
consortium (31% of all cases), suggesting that the frequency
of this subtype in AAs is similar to that of luminal A and
luminal B tumors (37% and 25%, respectively). The fre-
quency of luminal A tumors was overestimated (55%) when
relying on ER, PR and HER2 from medical records alone,
underscoring the importance of using central IHC staining
and additional markers, such as Ki67 or grade, to accurately
classify luminal tumors. Overall, this work highlights the
use of automated IHC-based methods to approximate
PAM50-based subtype frequencies and confirms a high
prevalence of basal-like breast cancer among AA women in
a large consortium.
Accurately distinguishing luminal A from luminal B breast
cancer, subtypes with distinct clinical outcome and poten-
tially different etiology, is a significant challenge in epidemi-
ologic studies. Moreover, because luminal A cases often
serve as the reference group in case-only analyses [1, 16],
Fig. 1 Frequency of immunohistochemistry (IHC)-based subtypes within prediction analysis of microarray 50 (PAM50)-based subtype categories. Black pie
slices represent the percentage of each PAM50-based subtype correctly identified using IHC-based definitions, while colored slices represent IHC-based
subtypes of misclassified cases. HR, hormone receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2
Table 3 Frequency of six-marker immunohistochemistry-
defined subtypesa, overall and by study site in the AMBER
consortium
IHC-based
definitiona
Overall
n (%)
CBCS
n (%)
WCHS
n (%)
BWHS
n (%)
Luminal A HR ≥10%, Ki67 <7% 512
(37)
233
(32)
146
(42)
133
(46)
Luminal B HR ≥10%, Ki67 ≥7% 333
(25)
212
(29)
73 (21) 48 (17)
ER-/HER2+ ER <10%, HER2+ 111 (8) 52 (7) 32 (9) 27 (9)
Basal-like HR <10%, HER2-,
antigenicity+
425
(31)
247
(33)
99 (28) 79 (28)
Total 1381 744 350 287
Unclassifiedb 171 75 57 39
CBCS percentages are weighted for study sampling scheme
ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IHC
immunohistochemistry, HR hormone receptor, CBCS Carolina Breast Cancer
Study, WCHS Women’s Circle of Health Study, BWHS Black Women’s
Health Study
aAntigenicity+ = CK5/6 ≥1% or EGFR ≥1%
bTumors with five-marker negative (n = 7), HER2-equivocal (n = 81), and missing
biomarker (n = 83) status remained unclassified
Table 2 Classification of basal-like breast cancer cases using
data from central immunohistochemistry assays in the AMBER
consortium
IHC-based
basal-like
classification
scheme
Number
(percentage)
of PAM50
basal-like
tumors
identified
by IHC
Number
(percentage)
of unclassified
(i.e. triple
negative,
non-PAM50
basal-like)c
Sensitivity
for PAM50
subtype
Specificity
for PAM50
subtype
Accuracy
for PAM50
subtype
HR-, HER2- 174 (84) - 84% 90% 88%
HR-, HER2-,
(EGFR+ or
CK5/6+)a
173 (83) 3 (1.4) 83% 91% 88%
HR-, HER2-,
CK5/6+b
110 (53) 86 (41) 53% 96% 81%
IHC immunohistochemistry, HR hormone receptor, HER2 human epidermal
growth factor receptor 2, EGFR epidermal growth factor receptor, CK5/6
cytokeratin 5/6, PAM50 prediction analysis of microarray 50
aEGFR+ and CK5/6+ defined as ≥ 1% staining in any core
bCK5/6+ defined as a weighted average ≥2% across all cores for a given case
cOf 210 IHC-based triple negative cases with PAM50 subtype
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improving accuracy for identifying luminal A tumors is crit-
ical for etiologic and survivorship studies of all subtypes.
Prat and colleagues reported that luminal A tumors could
be identified by their substantial (> 20%) expression of PR
[8], leading to the incorporation of quantitative PR data into
St. Gallen guidelines [3]. However, this observation was not
replicated in our study, suggesting that PR may not reliably
segregate luminal A and B tumors across different popula-
tions. On the other hand, we found that incorporating Ki67
data, as recommended by St. Gallen guidelines, improved
accuracy for luminal tumor classification in the AMBER
consortium. Moreover, the use of an automated scoring
algorithm afforded more precision in selecting Ki67 thresh-
olds, compared to manually estimating biomarker thresh-
olds. However, one challenge with utilizing Ki67 data is
the necessity of establishing study-specific standards [3];
the 7% Ki67 threshold optimized for the AMBER study is
lower than in other studies that used 14% or 20% thresh-
olds [15, 17]. Automated biomarker quantification methods,
as used in AMBER, calculate biomarker expression among a
range of cell types within a tumor, while manual review used
by other studies may exclude benign epithelium, immune
infiltrates, or stromal cells more accurately [7]. However, we
enriched for tumor epithelium in the AMBER consortium
by excluding tissue microarray (TMA) cores with low tumor
cellularity, and so it may be that Ki67 staining protocols and
scoring algorithms are merely difficult to standardize across
studies. Indeed, an international working group evaluating
inter-laboratory reproducibility for Ki67 showed that this
biomarker is challenging to harmonize, even across some of
the world’s most experienced laboratories [18]. Confidence
in our Ki67 threshold can be derived from its optimization
with respect to RNA-based subtype, while prior studies se-
lected study-specific Ki67 thresholds based on clinical out-
come [19, 20]. Given that both approaches have merit,
researchers should be guided by whether the goal is to study
breast cancer etiology or breast cancer outcomes. Import-
antly, our data suggest that combined tumor grade, taken ei-
ther from the clinical record or determined centrally,
distinguishes luminal tumors with similar accuracy to Ki67.
Thus, tumor grade could be used in epidemiologic studies
that do not have access to Ki67 data. Finally, findings from
the AMBER and other studies [14, 15] show that approxi-
mately 70% of PAM50-defined luminal B tumors lack HER2
protein expression, while approximately 10% of PAM50-
defined luminal A tumors express HER2, suggesting that
HER2 may not be useful for distinguishing luminal subtypes.
Indeed, we found that dropping HER2 from our IHC-based
classification scheme produced similar, if slightly improved,
accuracy for identifying luminal A and luminal B tumors.
Subtype classification based on absence of biomarker
expression is often deemed unreliable, and best practice
has dictated identifying a positive marker for each tumor
subtype. As such, expression of either EGFR or CK5/6
has been proposed for classification of basal-like breast
cancer [3]. Of 474 cases of triple negative breast cancer
in the AMBER consortium, only 7 (< 2%) lacked expres-
sion of both basal-like markers. This finding is in
marked contrast to previous studies, some of which re-
ported that up to 40% of triple negative cases are nega-
tive for both EGFR and CK5/6 [10, 11, 21]. However,
adjusting EGFR and CK5/6 thresholds in the AMBER
consortium to produce similar rates of triple negative
Table 4 Differences in age and menopausea status at diagnosis
across six-marker immunohistochemistry-defined subtypesb in
the AMBER consortium
Age ≥50
years,
n (%)
Age <50
years,
n (%)
OR
(95% CI)
Postmeno,
n (%)
Premeno,
n (%)
OR
(95% CI)
Luminal A 305 (39) 207 (34) 1 300 (39) 204 (35) 1
Luminal B 195 (25) 138 (23) 1.04
(0.79–1.38)
194 (25) 135 (23) 1.02
(0.77–1.36)
ER-/HER2+ 49 (6) 62 (10) 1.86
(1.23–2.82)
51 (7) 57 (10) 1.64
(1.08–2.30)
Basal-like 224 (29) 201 (33) 1.32
(1.02–1.71)
233 (30) 182 (31) 1.15
(0.88–1.49)
P valuec 0.008 0.107
Unclassified 93 78 93 72
Tumors with five-marker negative (n = 7), human epidermal growth factor 2 (HER2)-
equivocal (n = 81), and missing biomarker (n = 83) status remained unclassified
ER estrogen receptor, Postmeno postmenopausal, Premeno premenopausal
aThere were 25 cases with missing data on menopause status
bLuminal A: HR+, low Ki67; luminal B: HR+, high Ki67; ER-/HER2+: ER <10% and HER2-
positive; basal-like: HR-, HER2- and (EGFR+ or CK5/6+)
cChi-square test p value excludes unclassified cases
Table 5 Tumor characteristics associated with six-marker immunohistochemistry-based subtypesa in the AMBER consortium
IHC-based
subtype
Number High combined grade(3 vs. 1/2) Large tumor size
(>2 vs. ≤2 cm)
Positive lymph node status
(positive vs. negative)
High stage
(III/IV vs. I/II)
n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
Luminal A 512 78 (16) 1.00 (ref ) 198 (39) 1.00 (ref ) 196 (39) 1.00 (ref ) 69 (14) 1.00 (ref )
Luminal B 333 158 (48) 4.99 (3.61–6.91) 152 (46) 1.33 (1.01–1.76) 130 (40) 1.03 (0.77–1.37) 44 (14) 0.98 (0.66–1.48)
ER-/HER2+ 111 86 (82) 24.02 (13.82–41.75) 57 (51) 1.67 (1.11–2.53) 62 (58) 2.16 (1.41–3.31) 26 (24) 2.02 (1.21–3.36)
Basal-like 425 365 (90) 46.13 (30.90–68.86) 252 (59) 2.31 (1.78–3.00) 173 (41) 1.09 (0.84–1.42) 62 (15) 1.10 (0.76–1.60)
IHC immunohistochemistry, ER estrogen receptor, HER2 human epidermal growth factor receptor 2
aLuminal A: hormone receptor (HR)+, HER2-, low Ki67; luminal B: (HR+, HER2+) or (HR+, HER2-, high Ki67); ER-/HER2+: ER <10% and HER2-positive; basal-like: HR-,
HER2- and (EGFR+ or CK5/6+)
Tumors with five-marker negative (n = 7), HER2-equivocal (n = 93), and missing biomarker (n = 99) status excluded from analysis
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non-basal-like cases resulted in the misclassification of
almost half of all PAM50-defined basal-like cases as
triple negative non-basal-like, and this would likely im-
pede our ability to conduct adequately powered analyses
of basal-like etiology and survivorship patterns in the
AMBER consortium. An important distinction between
previous studies and our own is that previous studies
manually assessed IHC-based EGFR and CK5/6 expres-
sion [10, 11] and therefore counted only EGFR-positive
and CK5/6-positive tumor cells. We considered a case to
be antigen-positive when either the tumor or the sur-
rounding normal epithelium or stroma was positive for
either one of these markers. However, manual review of
a subset of PAM50-based basal-like cases revealed
extremely high agreement (>96%) between manual and
automated scoring of basal-like markers. An alternative
explanation for the discrepancy in number of triple
negative non-basal-like cases lies in the significant de-
cline in antigenicity of cut sections after several months
to one year of storage at room temperature, potentially
contributing to false negative biomarker status in studies
reporting higher percentages of quintuple negative
tumors [22, 23]. We maximized tissue antigenicity in the
AMBER study by using a nitrogen desiccation chamber
for storage of unstained slides. Finally, based on high
intratumoral heterogeneity for CK5/6 and EGFR, when
using TMAs our results support interpretation of these
biomarkers as antigenicity markers, such that any posi-
tivity should support classification of ER, PR, and HER2
negative samples as basal-like. In sum, given that a bio-
marker robustly expressed by all basal-like tumors has
not yet been identified, interpretation of CK5/6 and
EGFR as markers of tissue antigenicity may be reason-
able and, in our hands, yielded the highest sensitivity for
detecting PAM50-defined basal-like tumors.
Our study has both strengths and weaknesses. First, we
used data from TMAs comprising different core diameters
(0.6 mm and 1.0 mm). This approach may introduce tech-
nical sources of variability in biomarker expression and
affect the selection of biomarker thresholds. However, we
previously explored multiple sources of technical variabil-
ity [7], and optimized our IHC quantification methods
accordingly. We also strengthened our analysis through
validation of automated staining protocols guided by
pathologists, and through optimization of IHC-based clas-
sification using RNA-based multigene assays. Our prior
study [6], together with our unpublished observations,
provide reassurance that biomarker thresholds and sub-
type classification schemes described here are appropriate
for both white and African American breast cancer cases
in the CBCS, one of the three studies contributing to the
AMBER consortium. As such, we believe that our ap-
proach, with proper validation and methodological work
warranted in distinct study resources, is generalizable to
other studies using automated methods to classify breast
cancer subtype in racially diverse populations. It is note-
worthy that associations between subtype and tumor char-
acteristics in the AMBER consortium were similar to
those reported previously, albeit slightly stronger [24], per-
haps due to higher specificity/greater purity of the luminal
A reference group with the addition of Ki67 expression
data. Relative to luminal A tumors in the AMBER consor-
tium, all other subtypes had higher combined grade and
were larger, but only ER-/HER2+ tumors were more likely
to be lymph node positive and later-stage tumors. Stage at
diagnosis did not differ between luminal A and basal-like
tumors, a finding in line with SEER data [24]. These asso-
ciations with tumor characteristics underscore that basal-
like tumors tend to have more aggressive characteristics,
while luminal A tumors tend to be more indolent. These
associations have been relatively consistent across studies
and in different racially defined subpopulations [25–27].
Using central biomarker data in this consortium, we
showed that the frequency of basal-like breast cancer
ranged from 28% to 33% across contributing studies, con-
sistent with past studies in AAs using IHC-based subtype
classification [28–30] and PAM50 assays [31]. These fre-
quency estimates for basal-like tumors are consistently
higher than those reported in white subjects, which range
from 8% to 12% [24, 26, 31]. Conversely, luminal A tu-
mors are less frequent in AAs relative to white subjects,
comprising 32–46% of breast cancer cases across the
AMBER studies. A smaller study of approximately 150
AA women reported a similar frequency of luminal A tu-
mors [31], while > 50% of all breast tumors in white
women are luminal A tumors [26, 31]. Lower rates of
screening have been documented in studies of AA women
[32], potentially contributing to lower detection rates for
the more indolent luminal A breast cancers in AAs rela-
tive to white women. Screening data were not collected in
the AMBER studies, and so we were unable to consider
the effect of mode of detection on subtype frequency in
the present study. However, the work of our group and
others has identified etiologic factors associated with ER-
negative and basal-like breast cancer [16, 33–35], some of
which are differentially distributed by race [36, 37]. Al-
though beyond the scope of the present study, continued
analyses of etiologic exposure and mode of detection in
the context of accurate subtyping are needed to better
understand the underlying causes of breast cancer racial
disparities. Upon completion, the AMBER consortium will
comprise > 4000 cases of breast cancer in AAs, with
banked tumor tissue and > 4000 AA controls, with
extensive risk factor data harmonized. With approaches to
classifying tumor subtypes now well established in the
AMBER consortium, we will be able to better understand
the underlying etiology of more aggressive breast cancers
in AA women.
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Conclusions
In summary, using PAM50-validated IHC-based tumor
classification, we provide the largest dataset to date on the
frequency of breast cancer subtypes in AA women. Our
findings validate the use of automated IHC-based
methods to approximate PAM50-based subtype frequen-
cies and highlight high frequency of basal-like and low fre-
quency of luminal A breast cancer in a large consortium
of AA women.
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